Stuart L. Schreiber
Stuart L. Schreiber, Ph.D.
Schreiber is a world leader in chemical biology, using small molecules as probes in uncovering biological functions. He has provided some of the most significant small-molecule-based advances, including small-molecule probes of extremely difficult targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation of cells) that are at the root of human disease.
His development of diversity-oriented synthesis, and integration of human biology and chemistry to guide the development of safe and effective therapeutics, among others, have dramatically advanced chemical biology and contributed to its becoming a vibrant area of life science research. Numerous new drugs for various indications (organ transplantation, dendritic cell vaccination, leukemia, multiple myeloma, and solid tumors, including carcinomas and sarcomas) have been approved and are being developed in which therapeutic effects are the direct consequence of proteins and/or cellular control mechanisms revealed by Schreiber’s research.
Schreiber is the Morris Loeb Professor in the Department of Chemistry and Chemical Biology at Harvard University and a Howard Hughes Medical Institute investigator. He is an elected member of the National Academy of Sciences and the American Academy of Arts and Sciences. He is the recipient of numerous awards, including the Tetrahedron Prize for Creativity in Organic Chemistry, Charles Butcher Award in Genomics and Biotechnology, the Association of American Cancer Institutes Distinguished Scientist Award, and the Award for Outstanding Achievement in Chemistry in Cancer Research from the American Association for Cancer Research.
Schreiber was a professor at Yale University from 1981 to 1988, and became a member of Harvard’s Department of Chemistry and Chemical Biology in 1988.
He received his B.A. in chemistry from the University of Virginia and his Ph.D. in organic chemistry from Harvard University.